摘要
目的评价细胞因子诱导的杀伤（CIK）细胞联合化疗治疗晚期大肠癌的临床疗效。方法取外周血50ml，分离单个核细胞，体外经白细胞介素（IL）-2、干扰素γ（IFN-γ）、抗CD3单抗、IL-1刺激培养8d后获得CIK细胞。CIK细胞联合化疗组、行单纯化疗的同期配对晚期大肠癌组患者各50例，比较近期疗效及生存率，流式细胞术检测回输CIK细胞前后患者免疫学指标，并观察其生活质量及不良反应。结果CIK细胞治疗前患者外周血中CD3＋、CD4＋、CD8＋和NK细胞比例分别为（54．779±14．228）％、（30．821±11．554）％、（16．676±6．256）％、（18．705±9．347）％，治疗后分别为（65．236±14．901）％、（37．292±8．880）％、（25．229±6．711）％、（22．950±8．933）％，较治疗前均显著提高（P〈0．05）。CIK细胞联合化疗组患者生活质量明显改善，不良反应轻微。CIK细胞联合化疗组的疾病控制率（DCR）为64％（32／50），高于单纯化疗组的40％（20／50）（P〈0．05）。CIK细胞联合化疗组与单纯化疗组生存率差异无统计学意义（P〉0．05）。结论CIK细胞联合化疗可增强晚期大肠癌患者免疫功能，提高患者生活质量，有较好的临床疗效。
Objective To evaluate the clinical effects of cytokine-induced killer （CIK） ceils combined with chemotherapy on the treatment of patients with advanced colorectal cancer. Methods CIK cells were prepared from 50 ml peripheral blood mononuclear ceils by stimulated with IL-2, IFN-γ anti-CD3 monoclone antibody, IL-1 for 8 d. The clinical effects and survival rate were compared between CIK cells combined with chemotherapy group and the chemotherapy group （50 patients with advanced colorectal cancer for each）. T cells and NK cells of patients were tested by FCM before and after CIK cells treatment. The improvement of quality of life and toxicity of this therapy were observed. Results The percentages of CD3＋, CD4＋, CD8＋ T cells and NK cells were （54.779±14.228） %, （30.821±11.554） %, （16.676±6.256） %, （18.705±9.347） % before CIK cells transfusion. After transfusion, the percentages were （65.236±14.901） %, （37.292±8.880） %, （25.229± 6.711） %, （22.950±8.933） %, respectively. The percentages were expanded greatly （P 〈 0.05）. The patients quality of life were improved clearly with lower toxicity. The DCR of CIK cells combined with chemotherapy group （64 %, 32/50） was higher than the chemotherapy group （40 %, 20/50） （P 〈 0.05）. The survival rate between two groups had no statistical significance （P 〉 0.05）. Conclusion Administration of CIK cells combined with chemotherapy can enhance immune function in patients with advanced colorectal cancer and improve their quality of life, and get good clinical efficacy.
出处
《肿瘤研究与临床》
CAS
2012年第10期663-666,共4页
Cancer Research and Clinic
